Driving the news: San Francisco-based biotech Vaxart is working on a COVID vaccine that would be delivered in an oral tablet.

India’s Bharat Biotech advanced its nasal COVID-19 vaccine candidate into a phase 2 clinical trial earlier this fall.

What they’re saying: Vaxart founder and chief scientific officer Sean Tucker told Axios he started the company because he found it difficult to get his flu shot every year.

“I thought ‘Hey, if someone mailed me a tablet in the mail every year, I would take that vaccine all the time,'” Tucker said.